SEPN · ISSUER CIK 1984086
Septerna, Inc.
Between Jul 31, 2026 and Oct 28, 2026, 4 Septerna, Inc. insiders reported $0.00 of open-market purchases and $72.3M of sales on SEC Form 4.
↗4 insiders filed
Original Form 4 filings from Jul 31, 2026 to Oct 28, 2026. 5 of 6 sales were reported under a 10b5-1 plan.
$0.00Insider buying
$72.3MInsider selling
−$72.3MNet open-market
Oct 19, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 19, 202619:00 | Oct 15, 2026 | SEPN | President and COO | S · Sell10b5-1 | $37.41 | −4,000 | 174,209 | -2% | −$150K | ||
| Oct 19, 202619:00 | Oct 15, 2026 | SEPN | President and COO | M · Exercise10b5-1 | $6.81 | +4,000 | 178,209 | +2% | $27K | ||
| Sep 3, 202619:01 | Sep 1, 2026 | SEPN | SVP, Drug Discovery | S · Sell10b5-1 | $37.83 | −3,333 | 96,412 | -3% | −$126K | ||
| Sep 3, 202619:01 | Sep 1, 2026 | SEPN | SVP, Drug Discovery | M · Exercise10b5-1 | $2.76 | +3,333 | 99,745 | +3% | $9K | ||
| Aug 14, 202617:44 | Aug 12, 2026 | SEPN | 10% Owner · +5 joint | S · Sell10b5-1 | $50.27 | +147,200 | 6,068,391 | +2% | −$7.4M | ||
| Aug 14, 202617:11 | Aug 12, 2026 | SEPN | Director, 10% Owner · +4 joint | S · Sell | $42.50 | −1,493,000 | 725,443 | -67% | −$63.5M | ||
| Aug 13, 202619:00 | Aug 11, 2026 | SEPN | President and COO | S · Sell10b5-1 | $44.00 | −25,000 | 174,209 | -13% | −$1.1M | ||
| Aug 13, 202619:00 | Aug 11, 2026 | SEPN | President and COO | M · Exercise10b5-1 | $5.79 | +25,000 | 199,209 | +14% | $145K | ||
| Aug 5, 202619:00 | Aug 3, 2026 | SEPN | SVP, Drug Discovery | S · Sell10b5-1 | $34.47 | −3,334 | 96,412 | -3% | −$115K | ||
| Aug 5, 202619:00 | Aug 3, 2026 | SEPN | SVP, Drug Discovery | M · Exercise10b5-1 | $2.76 | +3,334 | 99,746 | +3% | $9K |